復星醫藥(02196.HK)控股子公司獲藥品註冊申請受理
格隆匯2月10日丨復星醫藥(02196.HK)公吿,上海復星醫藥(集團)股份有限公司(以下簡稱“公司”)控股子公司桂林南藥股份有限公司就注射用硫酸多黏菌素B(以下簡稱“藥品1”)、上海朝暉藥業有限公司就鹽酸拉貝洛爾注射液(以下簡稱“藥品2”)的藥品註冊上市申請已分別獲國家藥品監督管理局受理。
藥品1、藥品2均為化學藥品。藥品1擬用於對常規療法耐藥、對本品敏感的革蘭氏陰性菌感染(如銅綠假單胞菌感染等)。藥品2擬用於(1)嚴重高血壓,包括妊娠期重度高血壓;(2)在麻醉過程中控制低血壓。
截至2024年12月,集團(即公司及控股子公司/單位,下同)現階段針對藥品1、藥品2的累計研發投入分別約為人民幣488萬元、人民幣209萬元(未經審計)。
根據IQVIACHPA最新數據1,2023年,注射用硫酸多黏菌素B於中國境內(不包括港澳台地區,下同)的銷售額約為人民幣17.03億元、鹽酸拉貝洛爾製劑於中國境內的銷售額約為人民幣1.17億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.